The offering includes 21,052,632 shares of common stock alongside warrants to purchase up to 42,105,264 additional shares. These warrants carry an exercise price of $1.10 per share. Piper Sandler is serving as the sole manager for the transaction, which is expected to close around July 31, 2026, pending standard closing conditions.
Inovio Pharmaceuticals Prices $20 Million Public Offering
Inovio Pharmaceuticals is raising $20 million through a public offering of common stock and warrants, the company announced Tuesday. The Plymouth Meeting-based biotech firm, which specializes in DNA medicines for HPV-related diseases and cancer, finalized the deal at a combined price of $0.95 per share and warrant.
In addition to the primary sale, the underwriters hold a 30-day option to purchase an extra 3,157,894 shares and warrants to cover over-allotments. The company intends to use the capital to support its ongoing development of DNA medicine platforms. The securities were sold under a shelf registration statement declared effective by the SEC on July 10.
Comments (0)
No comments yet. Be the first!